[PDF][PDF] Efficacy and safety of low-dose versus standard-dose valganciclovir for prevention of cytomegalovirus disease in intermediate-risk kidney transplant recipients
MA Halim, T Al-Otaibi, O Gheith, H Adel, A Mosaad… - 2016 - researchgate.net
Materials and Methods: We randomized kidney transplant recipients (1: 1) to receive 450 mg
daily valganciclovir (group 1) or 900 mg daily valganciclovir (group 2) for the first 6 months …
daily valganciclovir (group 1) or 900 mg daily valganciclovir (group 2) for the first 6 months …
Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
MA Halim, T Al-Otaibi, O Gheith, H Adel… - … : Official Journal of the …, 2016 - europepmc.org
Objectives Prophylaxis for cytomegalovirus infection is highly recommended for kidney
transplant recipients. The use of daily 900 mg valganciclovir is the usual prophylactic dose …
transplant recipients. The use of daily 900 mg valganciclovir is the usual prophylactic dose …
Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients
MA Halim, T Al-Otaibi, O Gheith, H Adel, A Mosaad… - 2016 - pubmed.ncbi.nlm.nih.gov
Objectives Prophylaxis for cytomegalovirus infection is highly recommended for kidney
transplant recipients. The use of daily 900 mg valganciclovir is the usual prophylactic dose …
transplant recipients. The use of daily 900 mg valganciclovir is the usual prophylactic dose …